These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11571515)

  • 1. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
    Blatt J; Gold SH; Wiley JM; Monahan PE; Cooper HC; Harvey D
    Bone Marrow Transplant; 2001 Aug; 28(4):405-7. PubMed ID: 11571515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.
    Hicks K; Peng D; Gajewski JL
    Bone Marrow Transplant; 2002 Dec; 30(12):975-8. PubMed ID: 12476294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
    Brady KM; Easley RB; Tobias JD
    Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIIa (Novoseven) as a hemostatic agent.
    Hedner U
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):43-7. PubMed ID: 11735110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review.
    Franchini M; Veneri D; Lippi G
    Bone Marrow Transplant; 2007 Jun; 39(12):729-35. PubMed ID: 17417659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review of rFVIIa use in a tertiary care pediatric center.
    Heller M; Lau W; Pazmino-Canizares J; Brandão LR; Carcao M
    Pediatr Blood Cancer; 2008 May; 50(5):1013-7. PubMed ID: 17960639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation.
    Pihusch M; Bacigalupo A; Szer J; von Depka Prondzinski M; Gaspar-Blaudschun B; Hyveled L; Brenner B;
    J Thromb Haemost; 2005 Sep; 3(9):1935-44. PubMed ID: 16102099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
    Payne EM; Brett SJ; Laffan MA
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):397-402. PubMed ID: 16788316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
    Hoots WK
    Hematology Am Soc Hematol Educ Program; 2006; ():426-31. PubMed ID: 17124094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation.
    Karimi M; Zakerinia M; Khojasteh HN; Ramzi M; Ahmad E
    J Thromb Haemost; 2004 Oct; 2(10):1853-5. PubMed ID: 15456505
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
    Mathew P; Young G
    Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of off-label recombinant activated factor VII for multiple indications in children.
    Reiter PD; Valuck RJ; Taylor RS
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):233-40. PubMed ID: 17636185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force.
    Martinowitz U; Michaelson M;
    J Thromb Haemost; 2005 Apr; 3(4):640-8. PubMed ID: 15842347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.